Making RNA vaccines easier to swallow

    HealthMaking RNA vaccines easier to swallow
    - Advertisment -

    Making RNA vaccines easier to swallow

    A pill that releases RNA in the stomach could offer a new way to administer vaccines, or to deliver therapies for gastrointestinal disease.

    Anne Trafton / MIT News Office

    Like most vaccines, RNA vaccines have to be injected, which can be an obstacle for people who fear needles. Now, a team of MIT researchers has developed a way to deliver RNA in a capsule that can be swallowed, which they hope could help make people more receptive to them.

    In addition to making vaccines easier to tolerate, this approach could also be used to deliver other kinds of therapeutic RNA or DNA directly to the digestive tract, which could make it easier to treat gastrointestinal disorders such as ulcers.

    - Advertisement -

    “Nucleic acids, in particular RNA, can be extremely sensitive to degradation particularly in the digestive tract. Overcoming this challenge opens up multiple approaches to therapy, including potential vaccination through the oral route,” says Giovanni Traverso, the Karl van Tassel Career Development Assistant Professor of Mechanical Engineering at MIT and a gastroenterologist at Brigham and Women’s Hospital.

    In a new study, Traverso and his colleagues showed that they could use the capsule they developed to deliver up to 150 micrograms of RNA — more than the amount used in mRNA Covid vaccines — in the stomach of pigs.

    Oral drug delivery

    For several years, Langer’s and Traverso’s labs have been developing novel ways to deliver drugs to the gastrointestinal tract. In 2019, the researchers designed a capsule that, after being swallowed, can place solid drugs, such as insulin, into the lining of the stomach.

    The pill, about the size of a blueberry, has a high, steep dome inspired by the leopard tortoise. Just as the tortoise is able to right itself if it rolls onto its back, the capsule is able to orient itself so that its contents can be injected into the lining of the stomach.

    In 2021, the researchers showed that they could use the capsule to deliver large molecules such as monoclonal antibodies in liquid form. Next, the researchers decided to try to use the capsule to deliver nucleic acids, which are also large molecules.

    Nucleic acids are susceptible to degradation when they enter the body, so they need to be carried by protective particles. To test the particles, the researchers first injected them into the stomachs of mice, without using the delivery capsule. The RNA that they delivered codes for a reporter protein that can be detected in tissue if cells successfully take up the RNA. The researchers found the reporter protein in the stomachs of the mice and also in the liver, suggesting that RNA had been taken up in other organs of the body and then carried to the liver, which filters the blood.

    Next, the researchers freeze-dried the RNA-nanoparticle complexes and packaged them into their drug delivery capsules. Working with scientists at Novo Nordisk, they were able to load about 50 micrograms of mRNA per capsule, and delivered three capsules into the stomachs of pigs, for a total of 150 micrograms of mRNA. This is the more than the amount of mRNA in the Covid vaccines now in use, which have 30 to 100 micrograms of mRNA.

    In the pig studies, the researchers found that the reporter protein was successfully produced by cells of the stomach, but they did not see it elsewhere in the body. In future work, they hope to increase RNA uptake in other organs by changing the composition of the nanoparticles or giving larger doses. However, it may also be possible to generate a strong immune response with delivery only to the stomach, Abramson says.

    “There are many immune cells in the gastrointestinal tract, and stimulating the immune system of the gastrointestinal tract is a known way of creating an immune response,” he says.

    Immune activation

    The researchers now plan to investigate whether they can create a systemic immune response, including activation of B and T cells, by delivering mRNA vaccines using their capsule. This approach could also be used to create targeted treatments for gastrointestinal diseases, which can be difficult to treat using traditional injection under the skin.

    “When you have systemic delivery through intravenous injection or subcutaneous injection, it’s not very easy to target the stomach,” Abramson says. “We see this as a potential way to treat different diseases that are present in the gastrointestinal tract.”

    Novo Nordisk, which partially funded the research, has licensed the drug-delivery capsule technology and hopes to test it in clinical trials. The research was also funded by the National Institutes of Health, the National Science Foundation Graduate Research Fellowships Program, a PhRMA Foundation postdoctoral fellowship, the Division of Gastroenterology at Brigham and Women’s Hospital, and MIT’s Department of Mechanical Engineering.


    Reprinted with permission of MIT News (” in the footer

    - Advertisement -


    Please enter your comment!
    Please enter your name here

    Latest news

    NDDB to Execute Upgradation of Biocontainment Facility

    NDDB has executed projects of several bio-containment labs and associated infrastructure in livestock health sector across the country in...

    UN’s Development Goals: Rich Nations Lead While World’s Poor Lag Far Behind

    According to the ninth edition of the Sustainable Development Report released by the UN Sustainable Development Solutions Network, none...

    UNICEF-Backed Report Says Pollution Killed 1.69 Lakh Children in India in 2021

    The State of Global Air report published in partnership with the UN Children’s Fund (UNICEF) warns on Wednesday that...

    A New Way to Spot Life-threatening Infections in Cancer Patients

    Leuko, founded by a research team at MIT, is giving doctors a noninvasive way to monitor cancer patients’ health...
    - Advertisement -

    Water Shortages Feared as Hindu Kush Himalaya Sees Second-Lowest Snow Persistence on Record

    In the Ganges River Basin, there has been significant fluctuations in the past twenty-two years. Prior to 2024, the...

    PM Releases Seventeenth PM-KISAN Instalment of Rs. 20,000 Crores

    The prime minister lauded the use of technology in taking the benefits to the deserved beneficiaries and also credited...

    Must read

    NDDB to Execute Upgradation of Biocontainment Facility

    NDDB has executed projects of several bio-containment labs and...

    UN’s Development Goals: Rich Nations Lead While World’s Poor Lag Far Behind

    According to the ninth edition of the Sustainable Development...
    - Advertisement -

    More from the sectionRELATED
    Recommended to you